Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]
Business Overview:[1]IKSL is a technology-enabled healthcare solutions provider which offer a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. It partners with an outpatient and inpatient health care organizations, enabling them to deliver superior clinical care through afee for value model.
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | L&T Technology | 4416.10 | 36.63 | 46805.94 | 1.25 | 329.20 | 2.85 | 2979.50 | 15.80 | 28.29 | 11480.90 | 16.75 | 1277.90 | 328.70 | 7.56 | 13.92 | 0.10 |
| 2. | Inventurus Knowl | 1701.30 | 67.31 | 29205.05 | 0.00 | 138.40 | 50.24 | 355.69 | 48.19 | 35.01 | 1206.84 | 46.37 | 433.86 | 138.40 | 19.74 | 25.91 | 0.07 |
| 3. | Tata Technolog. | 651.05 | 38.10 | 26415.94 | 1.28 | 165.50 | 5.14 | 1323.33 | 2.07 | 25.80 | 5170.65 | 16.93 | 693.29 | 165.50 | 7.41 | 11.06 | 0.07 |
| 4. | Affle 3i | 1821.90 | 61.13 | 25629.98 | 0.00 | 110.51 | 20.13 | 646.72 | 19.13 | 16.82 | 2471.38 | 22.30 | 419.30 | 110.51 | 7.87 | 11.09 | 0.01 |
| 5. | Sagility | 52.02 | 30.48 | 24352.27 | 0.10 | 250.83 | 113.76 | 1658.50 | 25.17 | 9.58 | 6218.99 | 24.55 | 798.87 | 250.83 | 2.74 | 5.08 | 0.14 |
| 6. | Netweb Technol. | 3274.60 | 137.58 | 18551.88 | 0.08 | 31.43 | 20.05 | 303.72 | 20.98 | 32.45 | 1353.57 | 14.29 | 134.84 | 31.43 | 32.06 | 15.15 | 0.03 |
| 7. | Cyient | 1154.20 | 22.74 | 12823.42 | 2.25 | 142.90 | -34.47 | 1781.00 | -3.68 | 16.58 | 7328.40 | 13.90 | 563.86 | 117.36 | 2.30 | 8.87 | 0.08 |
| – | Median: 62 Co. | 312.57 | 31.26 | 873.82 | 0.0 | 10.5 | 20.5 | 114.16 | 20.98 | 16.12 | 266.21 | 14.48 | 30.44 | 10.11 | 3.38 | 9.45 | 0.07 |
Standalone figures in ₹ crores
| Dec 2023 | Dec 2024 | Jun 2024 | Jun 2025 | Mar 2024 | Mar 2025 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
Sales | 250 | 241 | 201 | 319 | 183 | 290 | 240 | 356 |
Expenses | 113 | 138 | 123 | 170 | 123 | 161 | 124 | 178 |
Operating Profit | 137 | 103 | 79 | 150 | 60 | 129 | 116 | 178 |
Other Income | 7 | 6 | 1 | 2 | 7 | 2 | 6 | 2 |
Profit before tax | 133 | 99 | 70 | 142 | 53 | 121 | 113 | 168 |
Tax % | 15% | 16% | 18% | 20% | 20% | 17% | 18% | 18% |
Net Profit | 113 | 83 | 57 | 113 | 43 | 100 | 92 | 138 |
EPS in Rs | 6.61 | 4.82 | 3.33 | 6.58 | 2.49 | 5.82 | 5.37 | 8.07 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
Sales | 161 | 203 | 388 | 418 | 560 | 759 | 873 | 973 | 1,207 |
Expenses | 139 | 149 | 252 | 252 | 329 | 444 | 478 | 546 | 647 |
Operating Profit | 22 | 54 | 136 | 166 | 231 | 316 | 394 | 427 | 560 |
Other Income | 0 | 0 | 31 | 16 | 1 | -3 | 33 | 15 | 12 |
Interest | 8 | 8 | 7 | 7 | 6 | 5 | 16 | 11 | 11 |
Depreciation | 5 | 10 | 36 | 26 | 19 | 20 | 22 | 29 | 31 |
Profit before tax | 8 | 36 | 123 | 148 | 208 | 288 | 390 | 402 | 529 |
Net Profit | 8 | 36 | 122 | 139 | 189 | 253 | 337 | 332 | 434 |
EPS in Rs | 10.51 | 44.55 | 148.09 | 168.19 | 11.04 | 14.83 | 19.72 | 19.35 | 25.29 |
Dividend Payout % | 0% | 0% | 16% | 14% | 485% | 66% | 0% | 0% | – |
Standalone figures in ₹ crores
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 17 | 17 | 17 | 17 | 17 |
Reserves | -40 | -2 | 221 | 368 | 501 | 622 | 811 | 1,210 | 1,462 |
Borrowings | 74 | 79 | 0 | 62 | 53 | 43 | 227 | 77 | 106 |
Other Liabilities | 58 | 66 | 141 | 62 | 133 | 154 | 101 | 101 | 194 |
Total Liabilities | 100 | 151 | 370 | 500 | 704 | 836 | 1,156 | 1,405 | 1,779 |
Fixed Assets | 16 | 32 | 36 | 72 | 63 | 49 | 116 | 101 | 1,015 |
Gross Block | 32.75 | 58.98 | 119.83 | 173.45 | 173.87 | 170.90 | 246.07 | 234.70 | – |
Accumulated Depreciation | 16.96 | 26.52 | 83.90 | 101.01 | 110.83 | 121.45 | 130.28 | 133.98 | – |
CWIP | 14 | 26 | 0 | 0 | 0 | 0 | 0 | 10 | 2 |
Investments | 4 | 4 | 5 | 16 | 16 | 19 | 473 | 734 | 8 |
Other Assets | 66 | 88 | 329 | 412 | 624 | 767 | 567 | 560 | 755 |
Total Assets | 100 | 151 | 370 | 500 | 704 | 836 | 1,156 | 1,405 | 1,779 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 16 | 52 | 141 | 168 | 237 | 248 | 119 | 274 |
Cash from Investing Activity | -21 | -38 | -80 | -165 | -81 | -140 | -149 | -104 |
Cash from Financing Activity | 5 | -2 | -36 | -32 | -54 | -148 | -186 | 24 |
Net Cash Flow | 0 | 12 | 25 | -30 | 102 | -40 | -216 | 194 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Debtor Days | 130 | 101 | 35 | 23 | 25 | 32 | 83 | 116 |
Inventory Days | – | – | – | – | – | – | – | – |
Days Payable | – | – | – | – | – | – | – | – |
Cash Conversion Cycle | 130 | 101 | 35 | 23 | 25 | 32 | 83 | 116 |
Working Capital Days | -80 | -38 | -6 | 3 | -55 | -39 | -8 | 93 |
ROCE % | – | 70% | – | 47% | 46% | 52% | 47% | 35% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
No credit ratings.
Nov 2025
Aug 2025
Jul 2025
May 2025
Feb 2025
Stock Analysis
Inventurus Knowledge Solutions Ltd. provides technology-enabled healthcare solutions through a care enablement platform, primarily serving physician enterprises in the US market.
The Analyst/Institutional Investor Meet originally scheduled for January 20, 2026, has been cancelled due to unforeseen scheduling exigencies. No new date has been announced.
Corporate Announcements
